Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240

AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836

α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868

Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain

DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439

The synaptic vesicle cycle: a cascade of protein–protein interactions

Südhof, T. C. (1995) · Nature · doi:10.1038/375645a0 · Cited by 1,991

Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal

Maroteaux, L., Campanelli, J., & Scheller, R. (1988) · Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02804.1988 · Cited by 1,646

Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes

Davidson, W. S., Jonas, A., Clayton, D. F., & George, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9443 · Cited by 1,622

Modulation of memory fields by dopamine Dl receptors in prefrontal cortex

Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593

NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded

Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., & Lansbury, P. T. (1996) · Biochemistry · doi:10.1021/bi961799n · Cited by 1,524

Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,520

Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology

Izco, M., Blesa, J., Schleef, M., Schmeer, M., Porcari, R., Al‐Shawi, R., Ellmerich, S., de Toro, M., Gardiner, C., Seow, Y., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.010 · Cited by 213

Impaired dopamine release in Parkinson’s disease

Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207

Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation

Chung, S. Y., Kishinevsky, S., Mazzulli, J. R., Graziotto, J. J., Mrejeru, A., Mosharov, E. V., Puspita, L., Valiulahi, P., Sulzer, D., Milner, T. A., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.012 · Cited by 204

Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease

McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203

Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

Maia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204

Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons

Reeve, A. K., Ludtmann, M. H. R., Angelova, P. R., Simcox, E. M., Horrocks, M. H., Klenerman, D., Gandhi, S., Turnbull, D. M., & Abramov, A. Y. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.166 · Cited by 204

α-Synuclein: Normal Function and Role in Neurodegenerative Diseases

Norris, E. H., Giasson, B. I., & Lee, V. M. ‐. (2004) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)60002-0 · Cited by 208

Glia and alpha-synuclein in neurodegeneration: A complex interaction

Brück, D., Wenning, G. K., Stefanova, N., & Fellner, L. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.003 · Cited by 213

Presynaptic regulation of dopaminergic neurotransmission

Schmitz, Y., Benoit‐Marand, M., Gonon, F., & Sulzer, D. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02050.x · Cited by 202

Functional Alterations to the Nigrostriatal System in Mice Lacking All Three Members of the Synuclein Family

Anwar, S., Peters, O. M., Millership, S. J., Ninkina, N. N., Doig, N. M., Connor‐Robson, N., Threlfell, S., Kooner, G., Deacon, R. M. J., Bannerman, D. M., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6194-10.2011 · Cited by 198

Parkinson's disease and α‐synuclein expression

Devine, M. J., Gwinn, K. A., Singleton, A., & Hardy, J. (2011) · Movement Disorders · doi:10.1002/mds.23948 · Cited by 207

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 201

Monomeric Synucleins Generate Membrane Curvature

Westphal, C. H., & Chandra, S. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.418871 · Cited by 202

Alpha-synuclein and transgenic mouse models

Fernagut, P., & Chesselet, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.001 · Cited by 210

α‐Synuclein produces a long‐lasting increase in neurotransmitter release

Liu, S., Ninan, I., Antonova, I., Battaglia, F., Trinchese, F., Narasanna, A., Kolodilov, N., Dauer, W., Hawkins, R. D., & Arancio, O. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600451 · Cited by 198

Folding and misfolding of alpha-synuclein on membranes

Dikiy, I., & Eliezer, D. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.09.008 · Cited by 204

A Combinatorial Code for the Interaction of α-Synuclein with Membranes

Kubo, S., Nemani, V. M., Chalkley, R. J., Anthony, M. D., Hattori, N., Mizuno, Y., Edwards, R. H., & Fortin, D. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504894200 · Cited by 199

Attenuation of dopamine transporter activity by α-synuclein

Wersinger, C., & Sidhu, A. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00097-1 · Cited by 197

The role of α-synuclein in neurodegenerative diseases

Bennett, M. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.010 · Cited by 198

Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity

Tabrizi, S. J. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2683 · Cited by 196

SDS-Induced Fibrillation of α-Synuclein: An Alternative Fibrillation Pathway

Giehm, L., Oliveira, C. L. P., Christiansen, G., Pedersen, J. S., & Otzen, D. E. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.060 · Cited by 198

Dopamine Signaling in Dorsal Versus Ventral Striatum: The Dynamic Role of Cholinergic Interneurons

Threlfell, S., & Cragg, S. J. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00011 · Cited by 200

Animal models of Parkinson's disease

Jackson-Lewis, V. R., Blesa, J., & Przedborski, S. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70057-8 · Cited by 199

Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation

Qin, Z., Hu, D., Han, S., Reaney, S. H., Monte, D. A. D., & Fink, A. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608126200 · Cited by 194

Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity

Luk, K. C., Covell, D. J., Kehm, V. M., Zhang, B., Song, I. Y., Byrne, M. D., Pitkin, R. M., Decker, S. C., Trojanowski, J. Q., & Lee, V. M.-Y. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.053 · Cited by 191

Disease model: Parkinson's disease

Shimohama, S., Sawada, H., Kitamura, Y., & Taniguchi, T. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00117-5 · Cited by 190

Biophysics of α-synuclein membrane interactions

Pfefferkorn, C. M., Jiang, Z., & Lee, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.07.032 · Cited by 190

Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies

Bourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bézard, E., Dehay, B., & Tsarbopoulos, A. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 202

Targets for neuroprotection in Parkinson's disease

Yacoubian, T. A., & Standaert, D. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.009 · Cited by 193

Mitochondrial involvement in Parkinson's disease

Orth, M. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00124-3 · Cited by 188

N-terminal Acetylation Stabilizes N-terminal Helicity in Lipid- and Micelle-bound α-Synuclein and Increases Its Affinity for Physiological Membranes

Dikiy, I., & Eliezer, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512459 · Cited by 194

Familial Mutants of α-Synuclein with Increased Neurotoxicity Have a Destabilized Conformation

Bertoncini, C. W., Fernández, C. O., Griesinger, C., Jovin, T. M., & Zweckstetter, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500288200 · Cited by 191

Mitophagy and Oxidative Stress: The Role of Aging

Gaetano, A. D., Gibellini, L., Zanini, G., Nasi, M., Cossarizza, A., & Pinti, M. (2021) · Antioxidants · doi:10.3390/antiox10050794 · Cited by 196

Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?

Bozzi, Y., & Borrelli, E. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.002 · Cited by 187

Structural Reorganization of α-Synuclein at Low pH Observed by NMR and REMD Simulations

Wu, K., Weinstock, D. S., Narayanan, C., Levy, R. M., & Baum, J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.063 · Cited by 188

shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model

Zharikov, A., Cannon, J. R., Tapias, V., Bai, Q., Horowitz, M. P., Shah, V., Ayadi, A. E., Hastings, T. G., Greenamyre, J. T., & Burton, E. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci64502 · Cited by 190

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α‐synuclein

Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184

Neuronal vulnerability, pathogenesis, and Parkinson's disease

Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25187 · Cited by 184

Alpha-Synuclein Is a Cellular Ferrireductase

Davies, P., Moualla, D., & Brown, D. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015814 · Cited by 184

Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model

Lee, K.-W., Chen, W. W., Junn, E., Im, J., Grosso, H., Sonsalla, P. K., Feng, X., Ray, N., Fernandez, J. R., Chao, Y., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.6513-10.2011 · Cited by 194

Dynamic regulation of the dopamine transporter

Mortensen, O. V., & Amara, S. G. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.066 · Cited by 181

Genes, proteins, and neurotoxins involved in Parkinson’s disease

Halbach, O. V. B. U., Schober, A., & KRIEGLSTEIN, K. G. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.002 · Cited by 180

Protein Oxidation in Aging: Does It Play a Role in Aging Progression?

Reeg, S., & Grune, T. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6062 · Cited by 191

Alpha-synuclein spreading in Parkinson’s disease

Recasens, A., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00159 · Cited by 192

Genetics and genomics of Parkinson’s disease

Lin, M. K., & Farrer, M. J. (2014) · Genome Medicine · doi:10.1186/gm566 · Cited by 183

Systematic Mutagenesis of α-Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities

Burré, J., Sharma, M., & Südhof, T. C. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3545-12.2012 · Cited by 188

Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?

Devoto, V. M. P., & Falzone, T. L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026294 · Cited by 184

Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation

Li, W., Lesuisse, C., Xu, Y., Troncoso, J. C., Price, D. L., & Lee, M. K. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1370-04.2004 · Cited by 185

Lewy Body Pathology in Alzheimer's Disease

Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177

Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization

Nielsen, M. S., Vorum, H., Lindersson, E., & Jensen, P. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101181200 · Cited by 185

A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases

Mandemakers, W. J., Morais, V. A., & Strooper, B. D. (2007) · Journal of Cell Science · doi:10.1242/jcs.03443 · Cited by 183

Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models

Su, L. J., Auluck, P. K., Outeiro, T. F., Yeger‐Lotem, E., Kritzer, J. A., Tardiff, D. F., Strathearn, K. E., Liu, F., Cao, S., Hamamichi, S., et al. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.004267 · Cited by 180

Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease

Nuber, S., Petrasch‐Parwez, E., Winner, B., Winkler, J., von Hörsten, S., Schmidt, T., Boy, J., Kuhn, M., Nguyen, H. P., Teismann, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3040-07.2008 · Cited by 182

Leucine-rich repeat kinase 2 associates with lipid rafts

Hatano, T., Kubo, S., Imai, S., Maeda, M., Ishikawa, K., Mizuno, Y., & Hattori, N. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm013 · Cited by 184

Genetics and Epigenetics of Parkinson's Disease

Coppedè, F. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/489830 · Cited by 182

α-synuclein aggregation and its modulation

Ghosh, D., Mehra, S., Sahay, S., Singh, P. K., & Maji, S. K. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.10.021 · Cited by 193

Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease

Gründemann, J., Schlaudraff, F., Haeckel, O., & Liss, B. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn084 · Cited by 173

Cell systems and the toxic mechanism(s) of α-synuclein

Cookson, M., & van der Brug, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.022 · Cited by 177

Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice

Freichel, C., Neumann, M., Ballard, T. M., Müller, V., Woolley, M. L., Ozmen, L., Borroni, E., Kretzschmar, H. A., Haass, C., Spooren, W. P. J. M., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.013 · Cited by 181

Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies

Bézard, E., Yue, Z., Kirik, D., & Spillantini, M. G. (2012) · Movement Disorders · doi:10.1002/mds.25108 · Cited by 193

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease

Ip, C. W., Klaus, L.-C., Karikari, A. A., Visanji, N. P., Brotchie, J. M., Lang, A. E., Volkmann, J., & Koprich, J. B. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0416-x · Cited by 173

Genetic mouse models of parkinsonism: Strengths and limitations

Fleming, S. M., Fernagut, P., & Chesselet, M. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.495 · Cited by 172

Synaptic failure and α‐synuclein

Calò, L., Węgrzynowicz, M., Santivañez‐Perez, J., & Spillantini, M. G. (2016) · Movement Disorders · doi:10.1002/mds.26479 · Cited by 179

α‐Synuclein and Polyunsaturated Fatty Acids Promote Clathrin‐Mediated Endocytosis and Synaptic Vesicle Recycling

Ben Gedalya, T., Loeb, V., Israeli, E., Altschuler, Y., Selkoe, D. J., & Sharon, R. (2009) · Traffic · doi:10.1111/j.1600-0854.2008.00853.x · Cited by 169

Fluorescent false neurotransmitter reveals functionally silent dopamine vesicle clusters in the striatum

Baptista, D., Schmitz, Y., Mészáros, J., Merchant, P., Hu, G., Li, S., Henke, A., Lizardi-Ortiz, J. E., Karpowicz, R. J., Morgenstern, T. J., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4252 · Cited by 172

Update on the genetics of Parkinson's disease

Gasser, T. (2007) · Movement Disorders · doi:10.1002/mds.21676 · Cited by 172

The Ubiquitin-Proteasome System in Neurodegeneration

McKinnon, C., & Tabrizi, S. J. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5802 · Cited by 175

Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies

Peng, C., Gathagan, R. J., & Lee, V. M. ‐. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.018 · Cited by 173

Sept4, a Component of Presynaptic Scaffold and Lewy Bodies, Is Required for the Suppression of α-Synuclein Neurotoxicity

Ihara, M., Yamasaki, N., Hagiwara, A., Tanigaki, A., Kitano, A., Hikawa, R., Tomimoto, H., Noda, M., Takanashi, M., Mori, H., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.019 · Cited by 165

Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse

Perfeito, R., Cunha‐Oliveira, T., & Rego, A. C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.042 · Cited by 169

Gene–environment interactions: Key to unraveling the mystery of Parkinson's disease

Gao, H., & Hong, J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.03.005 · Cited by 166

Increased striatal dopamine release and hyperdopaminergic‐like behaviour in mice lacking both alpha‐synuclein and gamma‐synuclein

Senior, S. L., Ninkina, N. N., Deacon, R. M. J., Bannerman, D. M., Buchman, V. L., Cragg, S. J., & Wade‐Martins, R. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06055.x · Cited by 160

Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse?

Sidhu, A., Wersinger, C., & Vernier, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-1112rev · Cited by 167

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era

Visanji, N. P., Brotchie, J. M., Kalia, L. V., Koprich, J. B., Tandon, A., Watts, J. C., & Lang, A. E. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.09.003 · Cited by 174

Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts

Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162

Synaptic dysfunction in Parkinson's disease

Bagetta, V., Ghiglieri, V., Sgobio, C., Calabresi, P., & Picconi, B. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380493 · Cited by 161

α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases

Ellis, C. E., Schwartzberg, P. L., Grider, T. L., Fink, D. W., & Nussbaum, R. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010316200 · Cited by 163

Plasma α-synuclein is decreased in subjects with Parkinson's disease

Li, Q., Mok, S. S., Laughton, K. M., McLean, C., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 161

Alpha‐Synuclein as a Pathological Link Between Chronic Traumatic Brain Injury and Parkinson's Disease

Acosta, S. A., Tajiri, N., de la Peña, I., Bastawrous, M., Sanberg, P. R., Kaneko, Y., & Borlongan, C. V. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24830 · Cited by 160

The Prion Protein Knockout Mouse

Steele, A. D., Lindquist, S. L., & Aguzzi, A. (2007) · Prion · doi:10.4161/pri.1.2.4346 · Cited by 159

Proteomic insights into an expanded cellular role for cytoplasmic lipid droplets

Hodges, B. D. M., & Wu, C. C. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r003582 · Cited by 159

Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies

Iwata, A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg283 · Cited by 165

Molecular motors implicated in the axonal transport of tau and α-synuclein

Utton, M. A., Noble, W. J., Hill, J. E., Anderton, B. H., & Hanger, D. P. (2005) · Journal of Cell Science · doi:10.1242/jcs.02558 · Cited by 172

α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra

McCormack, A. L., Mak, S. K., Henderson, J. M., Bumcrot, D. A., Farrer, M. J., & Monte, D. A. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012122 · Cited by 162

α-Synuclein–induced Aggregation of Cytoplasmic Vesicles inSaccharomyces cerevisiae

Soper, J. H., Roy, S., Stieber, A., Lee, E., Wilson, R. B., Trojanowski, J. Q., Burd, C. G., & Lee, V. M. ‐. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-08-0827 · Cited by 163

Protein aggregation: Mechanisms and functional consequences

Invernizzi, G., Papaleo, E., Sabaté, R., & Ventura, S. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.023 · Cited by 165

Genetic basis of Parkinson's disease: inheritance, penetrance, and expression

Gasser, T. (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s11639 · Cited by 169

Impairment of microtubule‐dependent trafficking by overexpression of α‐synuclein

Lee, H.-J., Khoshaghideh, F., Lee, S. B., & Lee, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05210.x · Cited by 163

Comparison of Structure and Dynamics of Micelle-bound Human α-Synuclein and Parkinson Disease Variants

Ulmer, T. S., & Bax, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507624200 · Cited by 156

Adult neurogenesis in Parkinson’s disease

Marxreiter, F., Regensburger, M., & Winkler, J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1062-x · Cited by 162

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Cole, T. A., Zhao, H. T., Collier, T. J., Sandoval, I. M., Sortwell, C. E., Steece‐Collier, K., Daley, B. F., Booms, A., Lipton, J. W., Welch, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.135633 · Cited by 171

Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice

Robertson, D. C., Schmidt, O., Ninkina, N. N., Jones, P. A., Sharkey, J., & Buchman, V. L. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02378.x · Cited by 154

A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in α-synuclein transgenic C . elegans

Kuwahara, T., Koyama, A., Koyama, S., Yoshina, S., Ren, C.-H., Kato, T., Mitani, S., & Iwatsubo, T. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn198 · Cited by 158

The Interaction of αB-Crystallin with Mature α-Synuclein Amyloid Fibrils Inhibits Their Elongation

Waudby, C. A., Knowles, T. P. J., Devlin, G. L., Skepper, J. N., Ecroyd, H. W., Carver, J. A., Welland, M. E., Christodoulou, J. C., Dobson, C. M., & Meehan, S. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.10.056 · Cited by 154

Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology

Ivanova, M. I., Lin, Y., Lee, Y., Zheng, J., & Ramamoorthy, A. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106507 · Cited by 157

Cytosolic Catechols Inhibit α-Synuclein Aggregation and Facilitate the Formation of Intracellular Soluble Oligomeric Intermediates

Mazzulli, J. R., Mishizen-Eberz, A. J., Giasson, B. I., Lynch, D. R., THOMAS, S. A., Nakashima, A., Nagatsu, T., Ota, A., & Ischiropoulos, H. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0896-06.2006 · Cited by 152

Human Wild-Type α-Synuclein Impairs Neurogenesis

Winner, B., Lie, D. C., Rockenstein, E. M., Aigner, R., Aigner, L., Masliah, E., Kuhn, H. G., & Winkler, J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.11.1155 · Cited by 156

Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines

Baptista, M. J., O’Farrell, C., Daya, S., Ahmad, R., Miller, D. W., Hardy, J., Farrer, M. J., & Cookson, M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01742.x · Cited by 154

Oxidative and nitrative alpha‐synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies

Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148

Summary

Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Manuel, J., Verdugo, G., Armanini, M. P., et al. (2013)

Increased striatal dopamine release and hyperdopaminergic‐like behaviour in mice lacking both alpha‐synuclein and gamma‐synuclein

Senior, S. L., Ninkina, N. N., Deacon, R. M. J., Bannerman, D. M., Buchman, V. L., Cragg, S. J., & Wade‐Martins, R. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06055.x · Cited by 160

Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein

Chadchankar, H., Ihalainen, J. A., Tanila, H., & Yavich, L. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.064 · Cited by 66

Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice

Ninkina, N. N., Tarasova, T. V., Chaprov, K., Roman, A. Y., Kukharsky, M. S., Колик, Л. Г., Ovchinnikov, R. K., Ustyugov, A. A., Дурнев, А. Д., & Buchman, V. L. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.026 · Cited by 35

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α‐synuclein

Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184